To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

Summary

To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).

Timeline

Start

2013-10

Primary completion

2015-09

Completion

2015-09

Outcome

Met primary endpoint

registry analysis (superiority or other test); Ranibizumab vs Sham With Ranibizumab; p = 0.0111; Mean Difference (Net) 2.78 (95% CI 0.40 to 5.16); Mixed Models Analysis NCT01846299 ↗

Drugs

Indications